Published in Am J Surg Pathol on January 01, 2003
Immunostaining patterns of myoepithelial cells in breast lesions: a comparison of CD10 and smooth muscle myosin heavy chain. J Clin Pathol (2004) 1.16
A subset of morphologically distinct mammary myoepithelial cells lacks corresponding immunophenotypic markers. Breast Cancer Res (2003) 0.97
Significance of immunohistochemistry in breast cancer. World J Clin Oncol (2014) 0.92
The use of P63 immunohistochemistry for the identification of squamous cell carcinoma of the lung. PLoS One (2010) 0.92
Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil– epirubicin–cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuvant chemotherapy. Breast Cancer Res Treat (2013) 0.91
New trends of immunohistochemistry for making differential diagnosis of breast lesions. Med Mol Morphol (2006) 0.90
D2-40: an additional marker for myoepithelial cells of breast and the precaution in interpreting tumor lymphovascular invasion. Int J Clin Exp Pathol (2011) 0.89
Comedo-DCIS is a precursor lesion for basal-like breast carcinoma: identification of a novel p63/Her2/neu expressing subgroup. Oncotarget (2013) 0.88
Expression and role of fibroblast activation protein-alpha in microinvasive breast carcinoma. Diagn Pathol (2011) 0.82
p63 Staining of myoepithelial cells in breast fine needle aspirates: a study of its role in differentiating in situ from invasive ductal carcinomas of the breast. J Clin Pathol (2002) 0.81
Encapsulated apocrine papillary carcinoma of the breast--a tumour of uncertain malignant potential: report of five cases. Virchows Arch (2009) 0.77
Lattice-based model of ductal carcinoma in situ suggests rules for breast cancer progression to an invasive state. PLoS Comput Biol (2014) 0.77
Invasive ductal carcinoma with in situ pattern: how to avoid this diagnostic pitfall? Am J Transl Res (2016) 0.75
p40 (ΔNp63) expression in breast disease and its correlation with p63 immunohistochemistry. Int J Clin Exp Pathol (2014) 0.75
Myoepithelial Cell Differentiation Markers in Ductal Carcinoma in Situ Progression. Am J Pathol (2015) 0.75
Adenoma of the nipple: A clinicopathological report of 13 cases. Oncol Lett (2014) 0.75
Novel Use for DOG1 in Discriminating Breast Invasive Carcinoma from Noninvasive Breast Lesions. Dis Markers (2016) 0.75
Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res (2004) 16.51
HER-2 testing in breast cancer using parallel tissue-based methods. JAMA (2004) 4.60
Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival. J Clin Oncol (2006) 3.42
CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: an immunohistochemical survey of 476 primary and metastatic carcinomas. Am J Surg Pathol (2003) 3.39
An international Ki67 reproducibility study. J Natl Cancer Inst (2013) 2.46
Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers. J Clin Oncol (2008) 2.38
Human epidermal growth factor receptor 2 assessment in a case-control study: comparison of fluorescence in situ hybridization and quantitative reverse transcription polymerase chain reaction performed by central laboratories. J Clin Oncol (2010) 2.28
Recommendations for improved standardization of immunohistochemistry. Appl Immunohistochem Mol Morphol (2007) 2.24
Implementation of a Canadian external quality assurance program for breast cancer biomarkers: an initiative of Canadian Quality Control in immunohistochemistry (cIQc) and Canadian Association of Pathologists (CAP) National Standards Committee/Immunohistochemistry. Appl Immunohistochem Mol Morphol (2009) 2.22
Pure epithelioid PEComas (so-called epithelioid angiomyolipoma) of the kidney: A clinicopathologic study of 41 cases: detailed assessment of morphology and risk stratification. Am J Surg Pathol (2011) 1.99
Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med (2009) 1.85
Automated quantitative analysis of estrogen receptor expression in breast carcinoma does not differ from expert pathologist scoring: a tissue microarray study of 3,484 cases. Breast Cancer Res Treat (2007) 1.75
Antibody-mediated blockade of integrin alpha v beta 6 inhibits tumor progression in vivo by a transforming growth factor-beta-regulated mechanism. Cancer Res (2008) 1.73
Thyroid transcription factor-1 expression in breast carcinomas. Am J Surg Pathol (2010) 1.65
Nuclear beta-catenin in mesenchymal tumors. Mod Pathol (2005) 1.60
Cytokeratins 7 and 20 in primary and secondary mucinous tumors of the ovary: analysis of coordinate immunohistochemical expression profiles and staining distribution in 179 cases. Am J Surg Pathol (2006) 1.44
Unmasking the mysteries of antigen or epitope retrieval and formalin fixation. Am J Clin Pathol (2004) 1.39
p53 and p21 form an inducible barrier that protects cells against cyclin E-cdk2 deregulation. Curr Biol (2002) 1.39
Intracystic papillary carcinomas of the breast: a reevaluation using a panel of myoepithelial cell markers. Am J Surg Pathol (2006) 1.36
Immunohistochemical expression of CDX2 in primary ovarian mucinous tumors and metastatic mucinous carcinomas involving the ovary: comparison with CK20 and correlation with coordinate expression of CK7. Mod Pathol (2006) 1.34
Perlecan protein core interacts with extracellular matrix protein 1 (ECM1), a glycoprotein involved in bone formation and angiogenesis. J Biol Chem (2003) 1.31
Optimal immunohistochemical markers for distinguishing lung adenocarcinomas from squamous cell carcinomas in small tumor samples. Am J Surg Pathol (2010) 1.22
Carcinoma of the collecting ducts of Bellini and renal medullary carcinoma: clinicopathologic analysis of 52 cases of rare aggressive subtypes of renal cell carcinoma with a focus on their interrelationship. Am J Surg Pathol (2012) 1.21
Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma: identification of a three-antibody immunohistochemical panel with maximal sensitivity and specificity. Mod Pathol (2006) 1.20
Best practices in diagnostic immunohistochemistry: hepatocellular carcinoma versus metastatic neoplasms. Arch Pathol Lab Med (2007) 1.19
Diagnostic utility of galectin-3 in thyroid cancer. Am J Pathol (2010) 1.14
Pharmacologically regulated in vivo selection in a large animal. Blood (2002) 1.12
Fluorescence in situ hybridization for the detection of t(X;18)(p11.2;q11.2) in a synovial sarcoma tissue microarray using a breakapart-style probe. Diagn Mol Pathol (2005) 1.09
Vaginal lymphatic channel location and its implication for intracavitary brachytherapy radiation treatment. Brachytherapy (2005) 1.08
Aberrant expression of epithelial and neuroendocrine markers in alveolar rhabdomyosarcoma: a potentially serious diagnostic pitfall. Mod Pathol (2008) 1.05
Determining true HER2 gene status in breast cancers with polysomy by using alternative chromosome 17 reference genes: implications for anti-HER2 targeted therapy. J Clin Oncol (2011) 1.05
p16 expression in primary ovarian mucinous and endometrioid tumors and metastatic adenocarcinomas in the ovary: utility for identification of metastatic HPV-related endocervical adenocarcinomas. Am J Surg Pathol (2007) 1.02
Immunohistochemistry for estrogen and progesterone receptors in the distinction of primary and metastatic mucinous tumors in the ovary: an analysis of 124 cases. Mod Pathol (2006) 1.01
Nonsmall cell lung carcinoma with neuroendocrine differentiation--an entity of no clinical or prognostic significance. Am J Surg Pathol (2007) 1.00
Best practices in diagnostic immunohistochemistry: myoepithelial markers in breast pathology. Arch Pathol Lab Med (2011) 0.99
Wilms tumor gene product: sensitive and contextually specific marker of serous carcinomas of ovarian surface epithelial origin. Appl Immunohistochem Mol Morphol (2004) 0.99
Biomarker panel diagnosis of thyroid cancer: a critical review. Expert Rev Anticancer Ther (2008) 0.97
Utility of a comprehensive immunohistochemical panel in the differential diagnosis of spindle cell lesions of the urinary bladder. Am J Surg Pathol (2009) 0.96
BAP1 immunohistochemistry and p16 FISH to separate benign from malignant mesothelial proliferations. Am J Surg Pathol (2015) 0.95
Ovarian atypical proliferative (borderline) mucinous tumors: gastrointestinal and seromucinous (endocervical-like) types are immunophenotypically distinctive. Int J Gynecol Pathol (2006) 0.94
Accuracy and precision in HER2/neu testing in breast cancer: are we there yet? Hum Pathol (2004) 0.94
IMP3 and GLUT-1 immunohistochemistry for distinguishing benign from malignant mesothelial proliferations. Am J Surg Pathol (2013) 0.93
Immunohistochemical markers of melanocytic tumors. Int J Surg Pathol (2003) 0.91
Utility of BAP1 Immunohistochemistry and p16 (CDKN2A) FISH in the Diagnosis of Malignant Mesothelioma in Effusion Cytology Specimens. Am J Surg Pathol (2016) 0.87
Analysis of gene expression, copy number and palindrome formation with a Dt40 enriched cDNA microarray. Subcell Biochem (2006) 0.86
Well-differentiated papillary mesothelioma with invasive foci. Am J Surg Pathol (2014) 0.83
Estrogen receptor alpha and progesterone receptor expression in ovarian adult granulosa cell tumors and Sertoli-Leydig cell tumors. Int J Gynecol Pathol (2007) 0.82
Relationship between clinical and pathologic features of ductal carcinoma in situ and patient age: an analysis of 657 patients. Am J Surg Pathol (2009) 0.82
Aggressive behavior of stage I ovarian mucinous tumors lacking extensive infiltrative invasion: a report of four cases and review of the literature. Int J Gynecol Pathol (2005) 0.82
Phyllodes tumor: Review of key imaging characteristics. Breast Dis (2015) 0.81
PAX8 expression in uterine adenocarcinomas and mesonephric proliferations. Int J Gynecol Pathol (2014) 0.80
Mixed carcinoid and adenocarcinoma of the appendix: report of 4 cases with immunohistochemical studies and a review of the literature. Appl Immunohistochem Mol Morphol (2004) 0.80
Immunohistochemical characterization of squamous differentiation and morular metaplasia in uterine endometrioid adenocarcinoma. Int J Gynecol Pathol (2013) 0.79
Guidelines for Pathologic Diagnosis of Malignant Mesothelioma: 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group. Arch Pathol Lab Med (2017) 0.79
HER2 in well differentiated breast cancer: is testing necessary? Breast Cancer Res Treat (2008) 0.78
BAP1 Immunohistochemistry and p16 FISH in the Diagnosis of Sarcomatous and Desmoplastic Mesotheliomas. Am J Surg Pathol (2016) 0.78
Testing for epidermal growth factor receptor in lung cancer: have we learned anything from HER-2 testing? J Clin Oncol (2004) 0.77
Begin at the beginning, with the tissue! The key message underlying the ASCO/CAP Task-force Guideline Recommendations for HER2 testing. Appl Immunohistochem Mol Morphol (2007) 0.77
Testing for HER-2/neu in breast cancer: is fluorescence in situ hybridization superior in predicting outcome? Adv Anat Pathol (2002) 0.77
The knowns and the unknowns in HER2 testing in breast cancer. Am J Clin Pathol (2011) 0.76
Concordance between human epidermal growth factor receptor 2 testing by reverse transcriptase polymerase chain reaction and fluorescent in situ hybridization. J Clin Oncol (2012) 0.75
GATA-3 expression in trophoblastic tissues: an immunohistochemical study of 445 cases, including diagnostic utility. Am J Surg Pathol (2015) 0.75
Fixation time does not affect expression of HER2/neu. Am J Clin Pathol (2011) 0.75
Do we need two more mesothelial markers? Hum Pathol (2005) 0.75
Immunohistochemistry cocktails are here to stay: Center for Medicare and Medicaid Services should revise its new reimbursement policy. Am J Clin Pathol (2012) 0.75
Comparative Sensitivities and Specificities of Antibodies to Breast Markers GCDFP-15, Mammaglobin A, and Different Clones of Antibodies to GATA-3: A Study of 338 Tumors Using Whole Sections. Appl Immunohistochem Mol Morphol (2016) 0.75
Tweaking and nudging toward improved-IHC quality. Appl Immunohistochem Mol Morphol (2009) 0.75
Somatostatin receptor 2a is a more sensitive diagnostic marker of meningioma than epithelial membrane antigen. Acta Neuropathol (2015) 0.75
Controversies and guidelines in tissue-based HER-2/neu testing in breast cancer. MLO Med Lab Obs (2002) 0.75
PAX8 expression in uterine malignant mesodermal mixed tumor (carcinosarcoma). Int J Gynecol Pathol (2014) 0.75
Immunohistochemistry cocktails are here to stay: Center of Medicare and Medicaid Services should revise its new reimbursement policy. Appl Immunohistochem Mol Morphol (2012) 0.75
Immunohistochemistry as an adjunct in the differential diagnosis of radiation-induced atypia versus urothelial carcinoma in situ of the bladder: a study of 45 cases. Hum Pathol (2012) 0.75
Course introduction and selection of immunohistochemical staining panels: principles and importance of incorporating clinical information. The 5th annual retreat for applied immunohistochemistry and molecular pathology january 30th-february 2, 2011, coral gables, Florida. Appl Immunohistochem Mol Morphol (2011) 0.75
Personalized medicine-molecular targeted cancer therapy. J Cell Mol Med (2009) 0.75